Pages that link to "Q33916776"
The following pages link to Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals (Q33916776):
Displaying 26 items.
- A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses (Q21135240) (← links)
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection (Q26775082) (← links)
- Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? (Q26865388) (← links)
- Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination (Q27008256) (← links)
- Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes (Q28647428) (← links)
- An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV. (Q30407263) (← links)
- Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. (Q34247289) (← links)
- Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens (Q34465228) (← links)
- Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals (Q34512293) (← links)
- Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways (Q34796206) (← links)
- Microparticles as immune regulators in infectious disease - an opinion (Q35928145) (← links)
- Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations (Q36238314) (← links)
- Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines (Q36849770) (← links)
- Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. (Q37643731) (← links)
- Dendritic cell based vaccines for HIV infection: the way ahead (Q38126373) (← links)
- Clinical applications of attenuated MVA poxvirus strain. (Q38156198) (← links)
- The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. (Q38725610) (← links)
- Microfluidic-based, live-cell analysis allows assessment of NK-cell migration in response to crosstalk with dendritic cells (Q39171809) (← links)
- Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors (Q39338087) (← links)
- Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation. (Q40751332) (← links)
- Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. (Q41031764) (← links)
- Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. (Q41731948) (← links)
- Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. (Q42610797) (← links)
- The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. (Q45325032) (← links)
- Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B (Q89633807) (← links)
- Immunity and vaccine development efforts against Trypanosoma cruzi (Q90077254) (← links)